ClinicalTrials.gg
CompletedNCT05023525Updated Sep 6, 2022

A Study of Safety, Tolerability, and Pharmacokinetics of Single Ascending Dosed of HSK31858 in Healthy Volunteers

A Phase 1 interventional study of HSK31858, tablet and Placebo, tablet in Healthy, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Completed at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-09-06.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a Phase I, single-dose escalation clinical trial for HSK31858 conducted in healthy volunteers. The safety, tolerability, and pharmacokinetics of HSK31858 tablet in healthy volunteers will be evaluated using a randomized, double-blind, placebo-controlled trial design.

02

Conditions studied

  • Healthy

Keywords

  • HSK31858
  • NCFBE
  • health
  • phase I
03

In context

Lead sponsor

Haisco Pharmaceutical Group Co., Ltd. is the lead sponsor of 118 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must have given written before any study-related activities are carried out and must be able to understand the full nature and purpose of the trial, including possible risks and adverse effects.
  2. Adult males and females, 18 to 55 years of age (inclusive) at Screening.
  3. ≥ 18.0 and ≤ 30.0 kg/m2, with a body weight ≥ 50 kg at Screening.
  4. Be nonsmokers (including tobacco, e-cigarettes, and marijuana) for at least 1 month prior to first study drug administration.
  5. Medically healthy without abnormalities at Screening and predose on Day 1, including:

    1. Physical examination without any clinically relevant findings.
    2. Systolic blood pressure in the range of 90 to 140 mmHg and diastolic blood pressure in the range of 50 to 90 mmHg after 5 minutes in supine position.
    3. Heart rate in the range of 50 to 100 bpm after 5 minutes rest in supine position.
    4. Body temperature, between 35.0°C and 37.7°C.
    5. No clinically significant findings in serum chemistry, hematology, coagulation, and urinalysis tests as deemed by the Investigator.
  6. Conventional 12-lead recording in triplicate (the mean of triplicate measurements will be used to determine eligibility at Screening and predose on Day 1) consistent with normal cardiac conduction and function, including:

    • Normal sinus rhythm with HR between 50 and 100 bpm, inclusive.
    • corrected using the Fridericia method (QTcF) between 350 to 450 msec for male subjects and 350 to 470 msec for female subjects, inclusive.
    • QRS duration of \< 120 msec.
    • PR interval of ≤ 210 msec.
    • Electrocardiogram morphology consistent with healthy cardiac ventricular conduction and normal rhythm, and with measurement of the QT interval.
    • No family history of short or long QT syndrome.
    • No history of risk factors for torsade de pointes or the diagnosis.
  7. Women of must be non-pregnant and non-lactating, and must use an acceptable, highly effective double from Screening until at least 30 days after last dose, including the Follow-up period. Double contraception is defined as a condom AND one other form of the following:

    • Established hormonal contraception (OCPs, long-acting implantable hormones, injectable hormones).
    • A vaginal ring or an IUD.
    • Documented evidence of surgical sterilization at least 6 months prior to Screening (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy, or bilateral oophorectomy for women or vasectomy for men [with appropriate post-vasectomy documentation of the absence of sperm in semen] provided the male partner is a sole partner).

    Women not of childbearing potential must be for ≥12 months. Postmenopausal status will be confirmed through testing of follicle-stimulating hormone (FSH) levels ≥ 40 IU/L at Screening for amenorrhoeic female subjects. Females who are abstinent from heterosexual intercourse will also be eligible.

    Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not considered highly effective methods of birth control. Subject complete abstinence for the duration of the study and for 1 month after the last study treatment is acceptable.

    Female subjects who are in same sex relationships are not required to use contraception.

    WOCBP must have a negative pregnancy test at Screening and Day 1 and be willing to have additional pregnancy tests as required throughout the study.

  8. Male subjects must be surgically sterile (> 30 days since vasectomy with no viable sperm), abstinent, or if engaged in sexual relations with a WOCBP, the subject and his partner must be surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy) or using an acceptable, highly effective contraceptive method from Screening until study completion, including the Follow-up period. Acceptable methods of contraception include the use of condoms and the use of an effective contraceptive for the female partner that includes: OCPs, long-acting implantable hormones, injectable hormones, a vaginal ring, or an IUD. Subjects with same sex partners (abstinence from penile-vaginal intercourse) are eligible when this is their preferred and usual lifestyle. Males must not donate sperm for at least 90 Days after the last dose of study drug.
  9. Have suitable venous access for blood sampling.
  10. Be willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions.
  11. Subjects must have no relevant dietary restrictions and be willing to consume standard meals provided during the confinement period.

Exclusion criteria

Exclusion Criteria:

  1. History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic or neurological disease, including any acute illness or surgery within the past 3 months determined by the PI to be .
  2. A primary diagnosis of or asthma as deemed by Investigator.
  3. Subjects has increased risk of infection:

    1. History and/or presence of tuberculosis (TB).
    2. Body temperature of > 37.7℃.
    3. Blood \<1.7 × 109/L, or white blood cell count \< 4.0×109/L (Screening and Day -1).
    4. Is in high risk-group (i.e., men who have had unprotected sex with men, women who have had sex without a condom with men who have sex with men, people who have had sex without a condom with a person who has lived or travelled in Africa, people who inject drugs, people who have had sex without a condom with somebody who has injected drugs, people who have caught another sexually transmitted infection, people who have received a blood transfusion while in Africa, eastern Europe, the countries of the former Soviet Union, Asia or central and southern America) for (HIV) infection within the last 6 months.
    5. Other latent or chronic infections (e.g., recurrent sinusitis, genital or ocular herpes, urinary tract infection) or at risk of infection (surgery, trauma, or significant infection) within 3 months of Screening, or history of skin abscesses within 3 months of Screening.
    6. Clinically significant lower respiratory tract infection not resolved within 4weeks prior to Screening, as determined by the PI.
    7. Volunteers with active or neoplastic disease in the previous 5 years other than superficial basal cell carcinoma.
    8. Disease history suggesting abnormal immune function or use of or plans to use systemic (e.g., , methotrexate, azathioprine, cyclosporine) or immunomodulating medications (e.g., interferon) during the study or within 4 months prior to the first study drug administration.
    9. Volunteers who have received live or in the 4 weeks prior to dosing.
    10. High-sensitivity C-reactive protein > (ULN) at Screening and on Day -1.
  4. Some subjects lacking functional Dipeptidyl peptidase 1 (DPP1) enzyme have been described to have periodontitis and palmoplantar hyperkeratosis:

    1. Subjects with signs of current gingivitis/periodontitis. Gingival evaluation (by inspection) will be performed by a dental hygienist or trained study physician.
    2. Subjects with a history of hyperkeratosis or erythema in palms or soles.
  5. Liver function test results (i.e., [AST], alanine aminotransferase [ALT], and gamma glutamyl transferase [GGT]) and total elevated more than 1.2 fold above the ULN.
  6. Positive test results for active HIV, surface antigen (HBsAg) or virus (HCV) antibodies (Abs).
  7. Presence or having sequelae of gastrointestinal, liver, kidney, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
  8. Estimated (CrCl) \< 60 mL/min using the Cockcroft-Gault formula or serum creatinine more than 1.5-fold above the ULN.
  9. History of alcohol abuse within 12 months prior to first study drug administration or positive alcohol breath test. Regular alcohol consumption defined as > 21 alcohol units per week (where 1 unit = 284 mL of beer, 25 mL of 40% spirit or a 125 mL glass of wine). Subject is unwilling to abstain from alcohol beginning 48 hours prior to admission to the CRU and during the confinement period.
  10. History of substance abuse within 12 months prior to first study drug administration or positive drug test results. Subjects with a positive toxicology Screening panel (urine test including qualitative identification of barbiturates, THC, amphetamines, benzodiazepines, opiates, and cocaine).
  11. Use of any prescription or over-the-counter medication (including herbal products, diet aids, and hormone supplements) within 14 days or 5 half-lives of the medication (whichever is longer) prior to the first study drug administration, except occasional use of paracetamol. Use of any IP or medical device within 30 days prior to Screening, or 5 half-lives of the product (whichever is the longest).
  12. Demonstrated clinically significant (required intervention e.g., emergency room visit, epinephrine administration) allergic reactions (e.g., food, drug, or atopic reactions, asthmatic episodes) which, in the opinion of the Investigator, would interfere with the volunteer's ability to participate in the trial.
  13. Known to any of the study drug ingredients.
  14. For women of , a positive serum pregnancy test at Screening or a positive urine pregnancy test with confirmatory serum pregnancy test on Day -1.
  15. Donation of blood or plasma within 30 days prior to first study drug administration, or loss of whole blood of more than 500 mL within 30 days prior to randomization, or receipt of a blood transfusion within 1 year of first study drug administration.
  16. Participation in another investigational clinical trial within 60 days prior to the first study drug administration and participation in more than 4 investigational drug studies within 1 year prior to Screening.
  17. Any other condition or prior therapy that in the opinion of the PI would make the volunteer unsuitable for this study, including inability to cooperate fully with the requirements of the study protocol or likelihood of noncompliance with any study requirements.
  18. Is an employee of an Investigator or Sponsor or an immediate relative of an Investigator.
  19. Pregnant or lactating at Screening or planning to become pregnant (self or partner) at any time during the study, including the Follow-up period.
  20. History of life-threatening infection (e.g., meningitis).
  21. Infections requiring parenteral antibiotics within the 6 months prior to Screening.
  22. Healthy volunteers with tattoos.
  23. Use of any IP or investigational medical device within 30 days prior to Screening, or 5 half-lives of the product (whichever is the longest) or participation in more than 4 investigational drug studies within 1 year prior to Screening.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    HSK31858, single dose

    5 cohorts with single doses starting with 5 mg HSK31858 as tablet.

    Drug: HSK31858, tablet

  • Placebo comparator
    Placebe, single dose

    5 cohorts with matching placebo to HSK31858 as tablet.

    Drug: Placebo, tablet

Interventions

  • Starting dose in single ascending dose: 5 mg

  • DrugPlacebo, tablet

    Matching placebo

06

What researchers measure

Primary outcomes

  1. The number and severity of treatment emergent adverse events (TEAEs)

    To assess the safety and tolerability of single oral dose of HSK31858 in healthy adult volunteers

    Time frame: 7 days after dosing

Secondary outcomes

  1. Cmax

    Maximum concentration

    Time frame: within 15 minutes before administration until 72 hours after administration

  2. Tmax

    Time to maximum concentration

    Time frame: within 15 minutes before administration until 72 hours after administration

  3. AUC0-last

    Area under the drug concentration-time curve, from time 0h to 72h

    Time frame: within 15 minutes before administration until until 72 hours after administration

  4. t½

    Apparent terminal half-life

    Time frame: within 15 minutes before administration until 72 hours after administration

  5. CL/F

    Apparent total clearance of drug

    Time frame: within 15 minutes before administration until 72 hours after administration

  6. Vd/F

    Apparent volume of distribution after oral administration

    Time frame: within 15 minutes before administration until 72 hours after administration

07

Study locations

1 site
  • Nucleus Network Pty Ltd
    Melbourne, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Apr 2022, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2021
First posted
Aug 26, 2021
StartActual
Oct 28, 2021
Primary completionActual
Apr 19, 2022
CompletionActual
Aug 16, 2022
Last update
Sep 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05023525
Collaborators
Haisco Pharmaceutical(Australia) Pty Ltd.
Responsible party
Sponsor
First posted
Aug 26, 2021
Start date
Oct 28, 2021
Primary completion
Apr 19, 2022
Completion
Aug 16, 2022
Last update
Sep 6, 2022

Study contacts

Ofer Gonen
principal investigator · Nucleus Network Pty Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Florensocatib

Start the discussion